Blog
-
-
A CRISPR gene editing treatment continues to show promise for two blood diseases
-
ASH: AstraZeneca’s Calquence, BeiGene’s Brukinsa turn heads with new data, putting Imbruvica on notice
-
Medtronic Amassing AI Capabilities With Acquisitions
-
Bristol Myers’ hopes for a CAR-T nod by year-end fade as COVID-19 delays FDA inspection
-
BioNTech to price vaccine below market rates, differentiate between regions
-
String of FDA approvals gives momentum to liquid biopsies
-
FDA advisers vote against Biogen’s Alzheimer’s drug, leaving its future in doubt
-
FDA greenlights Boston Scientific’s paclitaxel-coated Ranger balloon for peripheral artery disease
-
Insurers slam CMS proposal to hasten Medicare coverage of breakthrough medical devices